/
Pharmaceutical preparations company · NJ · FY ends Mar · Revenue $140M · 35.40% margin · $17M FCF
Margins and capital returns are both well above average: 23.32% operating margin, ROIC at 25.40%. Consistent with durable pricing power, though that alone doesn't make it a buy.
Revenue grew 48.4%, still solid.
Insufficient data to identify specific risks. Treat any missing metrics as a data gap, not a clean bill of health.
Profitability & Returns
Revenue (TTM)
$140M
▲ +48.4% YoY
Net Income (TTM)
$43M
▼ -121.5% YoY
Op. Margin
35.40%
▲ +1.5pp YoY
ROIC
58.28%
▲ +4.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$17M
▲ +244.2% YoY
Op. Cash Flow (TTM)
$19M
▲ +330.5% YoY
Net Debt
-$18M
Net Cash Position
Cash & Equiv.
$22M
5Y CAGR: +36.1%
Continue Research